First attenuated virus based vaccine against Rift Valley Fever

Live attenuated vaccine incorporating a variant of the Rift Valley Fever virus obtained in the laboratory by serial passages in the presence of a mutagenic agent, that could be the basis of a new vaccine strain with safety parameters not previously described.

Market need: La FieThe Rift Valley Fever is an emerging zoonotic viral disease with significant economic impact on animal health (that can also affect humans.
There is not a treatment or vaccine on the market. Development of a vaccine could be used to develop safe and effective control strategies, both for animal and human use.

Proposed solution: It´s been characterized a variant of the RVF virus obtained in the laboratory by serial passages in the presence of a mutagenic agent, favipiravir. This variant, called 40F-p8, was highly attenuated in immunodeficient mice extremely sensitive to viral infections, without altering its ability to induce a protective immune response in immunocompetent mice.
Furthermore, it´s been identified a number of specific mutations throughout the viral genome that can be potential virulence determinants.

Competitive advantages

Live attenuated vaccines induce long-lasting and broadly protective immunity after a single dose administration in both animals and humans.
Live attenuated vaccines induce long-lasting and broadly protective immunity after a single dose administration in both animals and humans.